BioTech IP Review

Adjuvant Treatment of HER2‑Positive Early Breast Cancer

U.S. Patent No. 11,077,189 B2

Assigned to: Genentech, Inc. (part of Roche)
Issued: August 3, 2021
Focus: Methods of using the monoclonal antibody pertuzumab in combination with other therapies for improved treatment outcomes in HER2‑positive early breast cancer.

What This Patent Covers

This patent protects:

  • Methods of adjuvant therapy using pertuzumab in combination with trastuzumab and chemotherapy for patients with operable HER2‑positive early breast cancer — a subtype of breast cancer characterized by overexpression of the HER2 receptor.
  • The claims specifically cover administering this combination after surgical tumor removal to significantly reduce the risk of cancer recurrence or death compared with standard trastuzumab plus chemotherapy alone.
  • The treatment approaches include defined dosing and therapeutic regimens documented to improve survival outcomes in clinical trials such as the APHINITY trial, which underlies much of the therapeutic rationale.

In practical terms, this patent covers not just the composition of pertuzumab itself, but how it’s used in combination therapy for early‑stage cancer post‑surgery, extending protection around the use of this biologic in a high‑value clinical setting.

Why It’s Important

1. Supports a Blockbuster Oncology Drug

Pertuzumab (marketed as Perjeta®) is one of Genentech’s major cancer treatments — widely used in combination therapy for HER2‑positive breast cancer, a serious and historically hard‑to‑treat subset of breast cancers.

2. Enhances Clinical Value

By patenting not only the molecule but specific adjuvant treatment methods, Genentech secures extended exclusivity around how the drug is used therapeutically. Protecting methods of use helps shield the product from biosimilar competition in key indications and can extend commercial lifecycle benefits even as some core formulation patents expire.

3. High Clinical and Commercial Impact

HER2‑positive breast cancer therapies are multi‑billion‑dollar markets globally, particularly in the adjuvant setting (post‑surgical treatment). Maximizing survival outcomes — and legally protecting the associated methods — contributes substantially to Genentech’s oncology franchise revenues.

4. Strategic Defense Against Biosimilars

Patents on specific methods of use like this one are key assets in legal strategies to defend against biosimilar challenges by offering multiple layers of exclusivity (composition, indication, regimen), which are especially important in biologics markets.

Summary

  • Patent: U.S. Patent No. 11,077,189 B2
  • Assignee: Genentech, Inc.
  • Issued: August 3, 2021
  • Focus: Methods for adjuvant treatment of HER2‑positive early breast cancer involving pertuzumab plus trastuzumab and chemotherapy
  • Importance: Helps protect and extend the commercial value of a blockbuster cancer therapy by legally securing its use in a high‑impact therapeutic setting.

Leave a comment